Please wait while the formulary information is being retrieved.
COMPRO (prochlorperazine)
- nausea and vomiting
- nausea and vomiting caused by cancer drugs
- Prochlorperazine Rectal Suppository
- Prochlorperazine Maleate Rectal Suppository
- Compro Rectal Suppository
- Compazine Rectal Suppository
- By Indication
25 mg rectal suppository
- Insert 1 suppository (25 mg) by rectal route 2 times per day
25 mg rectal suppository
- Insert 1 suppository (25 mg) by rectal route 2 times per day
25 mg rectal suppository
- Insert 1 suppository (25 mg) by rectal route 2 times per day
25 mg rectal suppository
- Insert 1 suppository (25 mg) by rectal route 2 times per day
Nausea and vomiting
- Insert 1 suppository (25 mg) by rectal route 2 times per day
- dofetilide
- Orap
- pimozide
- Tikosyn
Contraindicated
- cabergoline
Severe
Moderate
- Alagesic Lq
- amobarbital
- Amytal
- Aplenzin
- Ascomp With Codeine
- Belladonna-phenobarbital
- Bupap
- Buproban
- bupropion HBr
- bupropion HCl
- butabarbital
- Butalbital Compound W/codeine
- Butalbital Compound-codeine
- butalbital-acetaminop-caf-cod
- butalbital-acetaminophen
- butalbital-acetaminophen-caff
- butalbital-aspirin-caffeine
- Butisol
- Capacet
- codeine-butalbital-ASA-caff
- deferoxamine
- Desferal
- Donnatal
- Esgic
- Fioricet
- Fioricet With Codeine
- Fiorinal
- Fiorinal-codeine #3
- Forfivo Xl
- Luminal
- Margesic
- Marten-tab
- Mysoline
- Nembutal Sodium
- pentobarbital sodium
- phenobarb-hyoscy-atropine-scop
- phenobarbital
- phenobarbital sodium
- primidone
- secobarbital sodium
- Seconal Sodium
- Tencon
- Wellbutrin
- Wellbutrin Sr
- Wellbutrin Xl
- Zebutal
- Zyban
- Coma
- Extrapyramidal disease
- Neuroleptic malignant syndrome
- Parkinsonism
- Stupor
Contraindicated
- Acute myocardial infarction
- Benign prostatic hyperplasia with lower urinary tract sx
- Disease of liver
- Glaucoma
- Metabolic syndrome x
- Myocardial ischemia
- Organophos insecticide poisoning
- Pheochromocytoma
- Pregnancy
- Senile dementia
- Tardive dyskinesia
- Urinary retention
Severe
Moderate
- Alcoholism
- Anemia
- Angina
- Hyperglycemia
- Hyperprolactinemia
- Leukopenia
- Neutropenic disorder
- Obesity
- Orthostatic hypotension
- Seizure disorder
- Thrombocytopenic disorder
- Weight gain
COMPRO (prochlorperazine)
- nausea and vomiting
- nausea and vomiting caused by cancer drugs
- Akathisia
- Blurred vision
- Extrapyramidal disease
- Hypotension
- Syncope
- Tardive dyskinesia
- Constipation
- Decreased sweating
- Dizziness
- Drowsy
- Nasal congestion
- Orthostatic hypotension
- Sedation
- Sialorrhea
- Xerostomia
More Frequent
Severe
Less Severe
- Acquired dystonia
- Contact dermatitis
- Dysuria
- Pigmentary retinopathy
- Skin photosensitivity
- Abnormal sexual function
- Amenorrhea
- Breast engorgement
- Dyskinesia
- Erectile dysfunction
- Galactorrhea not associated with childbirth
- Hyperglycemia
- Hyperprolactinemia
- Hypertonia
- Irregular menstrual periods
- Mastalgia
- Symptoms of anxiety
- Weight gain
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Accidental fall
- Agranulocytosis
- Angioedema
- Exfoliative dermatitis
- Heat stroke
- Hemolytic anemia
- Hypothermia
- Idiopathic thrombocytopenic purpura
- Leukopenia
- Lupus-like syndrome
- Melanosis
- Neuroleptic malignant syndrome
- Neutropenic disorder
- Obstructive hyperbilirubinemia
- Oculogyric crisis
- Parkinsonism
- Priapism
- Prolonged QT interval
- Retinal disorder
- Seizure disorder
- Thrombocytopenic disorder
- Torsades de pointes
- Ventricular arrhythmias
- Visual changes
Less Severe
- Cataracts
- Fever
- Hyperkinesis
- Peripheral edema
- Photophobia
Contraindicated
Prochlorperazine
Do not use in pediatrics under 2 years of age or if child is under 20 lbs per manufacturer.
- 1 Day – 2 Years
- 1 Do not use in pediatrics under 2 years of age or if child is under 20 lbs per manufacturer.
Severe Precaution
None
Management or Monitoring Precaution
Prochlorperazine
Increased risk of extrapyramidal reactions. Avoid if suspected Reye syndrome.
- 2 Years – 18 Years
- Increased risk of extrapyramidal reactions. Avoid if suspected Reye syndrome.
Prochlorperazine
- Severity Level:
D
- Additional Notes: No fda category; neonatal complications( resp,gi,cns)w/exposure in 3rd trimester
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Prochlorperazine
Low amnt excr w/similar drug chlorpromazine, resulting in infant drowsiness
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Low amnt excr w/similar drug chlorpromazine, resulting in infant drowsiness |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Prochlorperazine
Neuro/Psych-Higher risk of tardive dyskinesia in the elderly. Anticholinergic effects may cause sedation, worsen cognitive impairment and increase fall risk. Increased risk of death in senile dementia. Cardiovascular-May cause orthostatic hypotension at higher doses. Gastrointestinal-May cause or worsen pre-existing constipation. Genitourinary-Best avoided in patients with urinary retention from any cause.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | Y | Y | Y | N | N |
BEERS: Y HEDIS: Y STOPP: Y
No Known Risk
None
- There may be a slightly increased risk of serious, possibly fatal side effects (such as heart failure, fast/irregular heartbeat, pneumonia) when this medication is used by older adults with dementia. This medication is not approved for the treatment of dementia-related behavior problems. Discuss the risks and benefits of this medication with the doctor.
| Cancer chemotherapy-induced nausea and vomiting | |
| R11.2 | Nausea with vomiting, unspecified |
| Z51.11 | Encounter for antineoplastic chemotherapy |
| Nausea and vomiting | |
| R11 | Nausea and vomiting |
| R11.2 | Nausea with vomiting, unspecified |
| 0-9 | A-Z |
|---|---|
| R11 | Nausea and vomiting |
| R11.2 | Nausea with vomiting, unspecified |
| R11.2 | Nausea with vomiting, unspecified |
| Z51.11 | Encounter for antineoplastic chemotherapy |
Formulary Reference Tool